Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemolysis is the breakdown or destruction of red blood cells (erythrocytes) resulting in the release of their contents, such as hemoglobin, into surrounding fluid (typically blood plasma). This process is normally part of erythrocyte turnover, with old or damaged RBCs removed mainly by the spleen and liver. Pathological hemolysis may be caused by disease, drugs, toxins, immune reactions, or mechanical stress (e.g., medical devices). Excessive hemolysis may outpace the body's ability to replace lost RBCs, resulting in hemolytic anemia and potential organ toxicity.
Mechanisms by which drugs cause hemolysis include immune-mediated destruction, oxidative damage, metabolic impairment, and direct membrane injury
13 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemolysis.